
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
From automated processes and modular instrumentation to specialist regulatory support, discover how you can streamline your workflow and set the pace in cell therapy.







